Sacituzumab Govitecan + Pembrolizumab in mNSCLC Sacituzumab govitecan combined with pembrolizumab shows promising efficacy and manageable safety in first-line metastatic NSCLC.

Sacituzumab Govitecan Plus Pembrolizumab as First-Line Therapy in mNSCLC: EVOKE-02 Study

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #SacituzumabGovitecan #Pembrolizumab #mNSCLC #NSCLC #EVOKE-02

Delayed TNBC readout for Datroway delivers survival benefit AstraZeneca and Daiichi Sankyo's Datroway comes good in the delayed TROPION-Breast02 trial as a frontline triple-negative breast cancer treatment.

#breastcancer #triplenegativebreastcancer #TNBC #AstraZeneca #AZ #Datroway #datopotamabderuxtecan #DaiichiSankyo #Oncology #TNBCpatients #TROPIONBreast02trial #metastaticTNBC #immunotherapy #TNBCtumours #Gilead #TROP2ADC #Trodelvy #sacituzumabgovitecan #PFSdata
zurl.co/t8A6T

Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer AbstractBackground. Most patients with metastatic breast cancer (MBC) are eligible for treatment with trastuzumab deruxtecan (T-DXd). No data are available

#BreastCancer #HER2 #T-DXd #SacituzumabGovitecan #OncoTwitter #MedicalWatch #MBC
academic.oup.com/jnci/advance...

This study provides a comprehensive profile of #SacituzumabGovitecan (SG) toxicity based on #clinicaltrials, the #FAERS database, and the DDInter database, identifying several new #adverseeffects (AEs) and drug–drug interactions associated with SG. #medsky

Read more: buff.ly/o8vzuAZ

The purpose of the #ASPRIA trial is to determine if a combination of two drugs, #Atezolizumab and #SacituzumabGovitecan, can be used to prevent recurrence in #TripleNegativeBreastCancer.
For more information call 877-338-7425 or visit:
www.dana-farber.org/clinical-tri...
#BreastCancer #TNBC

This retrospective study looked at real-world outcomes with #SacituzumabGovitecan among #BreastCancer pts with #CentralNervousSystem metastases.
🔓https://pubmed.ncbi.nlm.nih.gov/40038301/
✍️@antgiordanomd.bsky.social @stolaney1.bsky.social @drsarahsammons.bsky.social #LMD #CNS #MBC #leptomeningeal

The purpose of the #ASPRIAtrial is to determine if a combination of two drugs, #Atezolizumab and #SacituzumabGovitecan, can be used to prevent recurrence in #TripleNegativeBreastCancer.
For more information call 877-338-7425 or visit:
www.dana-farber.org/clinical-tri...
#BreastCancer #TNBC

📢Hot off the press: Q-TWiST Analysis of #SacituzumabGovitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− #MetastaticBreastCancer.
Read it now in Current Oncology 👇
www.mdpi.com/1718-7729/32...
@stolaney1.bsky.social @hoperugo.bsky.social

Check out this new plain language summary on the quality of life with #SacituzumabGovitecan treatment in the TROPiCS-02 study in participants with #BreastCcancer
www.tandfonline.com/doi/abs/10.1... @stolaney1.bsky.social @hoperugo.bsky.social